Follow-On Biologics: White House Calls 7 Years Of Exclusivity A "Generous Compromise"
This article was originally published in The Pink Sheet Daily
Executive Summary
Reply to Rep. Waxman notes that "a serious review of FDA's existing authorities is underway."